Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study

Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV

Mirum wins FDA approval for Atebrioz

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum's liver infection drug lowers virus levels in late-stage study

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $137.31

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

US FDA approves Mirum's drug for rare bone disorder

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM